FIELD: immunology; medicine.
SUBSTANCE: invention relates to a method for treating the symptoms of an initial episode of a disease associated with vWF, in particular thrombocytopenic purpura (TTP), as well as the use of a kit containing a container with a polypeptide having two single immunoglobulin variable domains (ISVD), and instructions for use, where each ISVD directed against human vWF is presented under SEQ ID NO: 19 to treat the symptoms of an initial episode of TTP.
EFFECT: invention provides an effective treatment for an initial episode of TTP that is more severe and difficult to treat than a recurrent episode.
16 cl, 5 dwg, 10 tbl, 22 ex
| Title |
Year |
Author |
Number |
| METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND THEIR USE |
2015 |
|
RU2807602C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES |
2017 |
- Kannicht, Christoph
- Winge, Stefan
- Kohla, Guido
- Solecka-Witulska, Barbara
|
RU2776807C2 |
| TREATMENT METHODS FOR HEMOPHILIA A |
2019 |
- Innes, Alison
- Katragadda, Suresh
- Rice, Kara
- Rudin, Dan
- Seth Chhabra, Ekta
- Wong, Nancy
|
RU2812863C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS |
2017 |
- Kannicht, Christoph
- Solecka-Witulska, Barbara
- Winge, Stefan
- Schwientek, Tilo
|
RU2782212C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES |
2015 |
- Kannicht, Christoph
- Solecka, Barbara
- Kohla, Guido
- Winge, Stefan
|
RU2714154C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION |
2014 |
- Demopulos Gregori A.
- Dadler Tomas
- Shveble Khans-Vilkhelm
|
RU2718850C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM |
2018 |
- Seregin, Alexey
- Liu, Tongyao
- Patarroyo-White, Susannah
- Drager, Douglas
- Peters, Robert T.
- Liu, Jiayun
|
RU2819144C2 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE |
2018 |
- Evelet, Devid
- Dzhenkins-Evelet, Dzhennifer
- Subramaniam, Amutakannan
- Bredshou, Ralf
|
RU2811435C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII |
2015 |
|
RU2721910C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES |
2018 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2794170C2 |
